Trial | Detection technique | Treatment | PFS (months) | HR for PFS (95% CI) | OS (months) | HR for OS (95% CI) | Reference |
---|---|---|---|---|---|---|---|
TAILOR | Sequencing | Erlotinib | 2.4 | 0.71 (0.53–0.95) | 5.4 | 0.73 (0.53–1.00) | [18] |
Docetaxel | 2.9 | 8.2 | |||||
DELTA | PCR-based methods | Erlotinib | 1.3 | 1.45 (1.09–1.94) | 9.0 | 0.98 (0.69–1.39) | [19] |
Docetaxel | 2.9 | 10.1 | |||||
CTONG0806 | DNA sequencing | Gefitinib | 1.7 | 0.53 (0.38–0.75) | 9.6 | 0.72 (0.49–1.04) | [20] |
ARMS | Pemetrexed | 5.6 | 12.4 |